ArticleJournal of multidisciplinary healthcare2025
A Pharmacist-Led VTE Management Program in Orthopedic Surgery Associated with Reduced Venous Thromboembolism and Increased Pharmacological Prophylaxis: A Retrospective Study.
Article in Journal of multidisciplinary healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to develop and assess the impact of a pharmacist-led, technology-supported venous thromboembolism (VTE) management program on improving VTE prophylaxis and incidence in patients undergoing orthopaedic surgery. Patients and Methods: This was a retrospective, observational study with a pre-post design conducted in the trauma and joint ward of the Orthopaedic Department of a tertiary hospital in Chongqing, China. Surgical patients were included from the period before (December 2022 to May 2023) and after (June to November 2023) the implementation of pharmacist-led VTE management program (PL-VTEMP), in which pharmacists conducted standardized VTE risk verification and proactive medication monitoring. Primary endpoints included VTE incidence and prophylactic pharmacotherapy rate. Multivariable logistic regression was used to adjust for potential confounders, along with an E-value analysis to assess robustness to unmeasured confounding. Results: In total, 651 participants were included (322 in the pre-program group and 329 in the post-program group). Following the implementation of pharmacist-led VTE management program, the incidence of VTE decreased significantly (7.8% vs 2.7%, p = 0.004) and the proportion of patients receiving pharmacological prophylaxis increased significantly among high-risk patients in the post-program group (51.6% vs 33.9%, p < 0.01). The pharmacist-led VTE management program was identified as a protective factor for VTE prevention in multivariate regression model (OR 0.223, 95% confidence interval [CI] 0.093-0.535). Despite the average duration of drug prophylaxis not significantly increased to match guideline recommendations (7.18 days vs 6.80 days, p > 0.05), the proportion of patients receiving oral sequential anticoagulants had risen (29.4% vs 2.3%, p < 0.001). No significant differences were observed in the incidence of bleeding. Conclusion: This study demonstrated the benefits of pharmacist-led VTE management program as thromboprophylaxis in patients undergoing orthopaedic surgery. Clinical pharmacists have the potential to be core members of the VTE management team.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.